Five strategies for meeting the requirements of Project Optimus and improving the chances of approval
The study designs and dose-finding strategies that have dominated decades of oncology drug development are becoming obsolete as the FDA’s Project Optimus takes full effect. The agency is now heavily scrutinizing Phase 1 and 2 studies to see whether they identify the safest and most effective dose—while this change seems abrupt, it’s loomed over the field for a long time.
We’ve helped our clients adapt to the new standards with five best practices outlined in this article.
Related Insights
Webinar
Advancing mRNA-based drug development and vaccine manufacturing
Jul 1, 2024
Webinar
Navigating the complexities of AML drug development
Oct 30, 2024
Blog
PD-1 inhibitors face scrutiny in esophageal cancer: Key takeaways for drug developers
Oct 4, 2024
Article
New endpoints for early-stage cancer are gaining regulatory traction
Jan 28, 2022
Blog
Making cell and gene therapy more accessible in the treatment of solid tumors
Jun 4, 2024
Article
Q&A Project Optimus: What you need to know
Oct 11, 2022
Webinar
Challenges and best practices for developing Antibody-Drug Conjugates (ADCs)
Nov 12, 2024
Playbook
Are you using real-world evidence?
Feb 1, 2023
Blog
Innovative modeling method could speed patient access to critical IO therapies
Jan 4, 2023
Article
Relyvrio Approval: Lessons Learned
Oct 31, 2022
Blog
Navigating the Joint Clinical Assessment (JCA) implementation: An analysis of EU member states readiness, challenges and opportunities for harmonization
Jan 9, 2025
Video
How to transition existing trials under EU-CTR
Feb 1, 2023
Related Insights
Webinar
Advancing mRNA-based drug development and vaccine manufacturing
Jul 1, 2024
Webinar
Navigating the complexities of AML drug development
Oct 30, 2024
Blog
PD-1 inhibitors face scrutiny in esophageal cancer: Key takeaways for drug developers
Oct 4, 2024
Article
New endpoints for early-stage cancer are gaining regulatory traction
Jan 28, 2022
Blog
Making cell and gene therapy more accessible in the treatment of solid tumors
Jun 4, 2024
Article
Q&A Project Optimus: What you need to know
Oct 11, 2022
Webinar
Challenges and best practices for developing Antibody-Drug Conjugates (ADCs)
Nov 12, 2024
Playbook
Are you using real-world evidence?
Feb 1, 2023
Blog
Innovative modeling method could speed patient access to critical IO therapies
Jan 4, 2023
Article
Relyvrio Approval: Lessons Learned
Oct 31, 2022
Blog
Navigating the Joint Clinical Assessment (JCA) implementation: An analysis of EU member states readiness, challenges and opportunities for harmonization
Jan 9, 2025
Video
How to transition existing trials under EU-CTR
Feb 1, 2023